Nature Reviews Clinical Oncology

简称 NAT REV CLIN ONCOL ·ENGLAND ·出版周期 Monthly ·年均收录 49 篇

82.2

最新影响因子

1.20%

自引率

很难

投稿难度

较慢,6-12周

审稿周期

期刊简介

Nature Reviews Clinical Oncology是一本国际知名的肿瘤学综述期刊，ISSN号为1759-4774，由Springer Nature出版社出版，出版地为英国，出版周期为月刊。该期刊的影响因子较高，属于SCI收录期刊，在中科院分区中通常位列医学大类1区或肿瘤学小类1区，但并非开放获取（OA）期刊。其发文特点以高质量的综述文章为主，涵盖肿瘤学领域的临床研究、治疗进展、分子机制、流行病学及转化医学等方向，尤其注重对最新研究进展的深度分析和未来趋势的展望。杂志在学术圈享有较高声誉，内容严谨且权威，但因其综述性质，原创性研究较少，且投稿难度较大，对作者学术背景要求较高，可能存在综述类文章引用波动性较大的风险。总体而言，该期刊是肿瘤学领域的重要参考来源，适合高水平的临床与科研人员阅读和投稿。

影响因子趋势

近期发表

Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology 2026-09-03

Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC 2026-08-27

Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems 2026-08-26

Exploring the landscape of targetable alterations in patients with glioblastoma 2026-08-19

Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma 2026-08-12

How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease 2026-08-11

The proteome comes of age, but precision oncology needs functional maps 2026-08-10

AI-based augmentation of oncology clinical trials 2026-08-07

HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL 2026-08-07

Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC 2026-08-04